ArticleNeuro-oncology2018
Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T.
Article in Neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04233788 (Metabolic Characterization of Space Occupying Lesions of the Brain Using in Vivo MR-), which is not on this map. Cited by 105 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Metabolic Characterization of Space Occupying Lesions of the Brain Using in Vivo MR- (Spectroscopic) Imaging at 3 Tesla and 7 Tesla
Who cites it
105 citing papers in PubMed, 3 syntheses or guidelines pooled it, 162 citations in OpenAlex.
- Quantitative Consistency of Amide Proton Transfer-Weighted MRI for Brain Tumor Differentiation: Systematic Review of Clinical Evidence.Tomography (Ann Arbor, Mich.) · 2026Pooled it
- Ultra-High-Field MRI in the Diagnosis and Management of Gliomas: A Systematic Review.Frontiers in neurology · 2022Pooled it
- Endogenous Chemical Exchange Saturation Transfer MRI for the Diagnosis and Therapy Response Assessment of Brain Tumors: A Systematic Review.Radiology. Imaging cancer · 2020Pooled it
- Identification and validation of an autophagy-related signature for predicting survival in lower-grade glioma.Bioengineered · 2021Trial
- Diagnostic Accuracy of APTw and NOEw MRI Metrics for IDH Mutation and 1p/19q Codeletion Prediction in Gliomas.NMR in biomedicine · 2026Article
- APTw CEST MRI in therapy-naive IDH-wildtype glioblastoma: insights into tumor heterogeneity and molecular subtypes.Journal of neuro-oncology · 2026Article
- CEST MRI: Translational prospects for intervertebral disc degeneration - from basic research to clinical applications.Journal of orthopaedic translation · 2026Review
- Imaging biomarkers for detecting IDH mutations and monitoring response to novel targeted therapies: Current insights and future perspectives.Neuro-oncology · 2026Review
- Dynamic Transitions for Fast Joint Acquisition and Reconstruction of CEST-Magnetic resonance in medicine · 2026Article
- Single-breath-hold 3D abdominal metabolic MRI enables label-free diagnosis of liver cancer.Nature communications · 2026Article
- Assessment of multimodal CEST, perfusion and diffusion MRI for predicting clinical outcome of patients with diffuse glioma following surgery at baseline before radiotherapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Amide proton transfer-weighted (APTw) CEST MRI in clinical routine for single time point diagnosis of pseudoprogression in IDH-wildtype glioblastoma.Neuro-oncology · 2026Article
- Detection of Aggressive Mesenchymal Glioblastoma by Mannose-Weighted CEST MRI.bioRxiv : the preprint server for biology · 2026Article
- TNMR in biomedicine · 2026Article
- Spatial tumour characteristics as an indirect marker of metabolic dysregulation: evaluation for non-invasive IDH-genotyping of glioma using hybrid [18 F]FET-PET/MRI.European journal of nuclear medicine and molecular imaging · 2026Article
- Accelerating CEST MRI through complementary undersampling and multi-offset transformer reconstruction.Communications engineering · 2026Article
- Prediction of MGMT promoter methylation in glioblastoma and grade 4 astrocytoma using fluid-suppressed chemical exchange saturation transfer MRI and machine learning-based segmentation.Frontiers in oncology · 2026Article
- Interpreting amide proton transfer-weighted imaging contrast between normal and tumor brain tissues using the asymmetry analysis method at 4.7 T.Magnetic resonance in medicine · 2026Article
- Field strength-dependent sensitivity of chemical exchange saturation transfer: a methodological comparison of 3 Tesla and 7 Tesla in a clinical cohort.Brain communications · 2026Article
- CEST Contrasts Exhibit Significant Regional Variations in the Human Brain at 3 T.NMR in biomedicine · 2025Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early identification of prognostic superior characteristics in glioma patients such as isocitrate dehydrogenase (IDH) mutation and O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is of great clinical importance. The study purpose was to investigate the non-invasive predictability of IDH mutation status, MGMT promoter methylation, and differentiation of low-grade versus high-grade glioma (LGG vs HGG) in newly diagnosed patients employing relaxation-compensated multipool chemical exchange saturation transfer (CEST) MRI at 7.0 Tesla. Methods: Thirty-one patients with newly diagnosed glioma were included in this prospective study. CEST MRI was performed at a 7T whole-body scanner. Nuclear Overhauser effect (NOE) and isolated amide proton transfer (APT; downfield NOE-suppressed APT = dns-APT) CEST signals (mean value and 90th signal percentile) were quantitatively investigated in the whole tumor area with regard to predictability of IDH mutation, MGMT promoter methylation status, and differentiation of LGG versus HGG. Statistics were performed using receiver operating characteristic (ROC) and area under the curve (AUC) analysis. Results were compared with advanced MRI methods (apparent diffusion coefficient and relative cerebral blood volume ROC/AUC analysis) obtained at 3T. Results: dns-APT CEST yielded highest AUCs in IDH mutation status prediction (dns-APTmean = 91.84%, P < 0.01; dns-APT90 = 97.96%, P < 0.001). Furthermore, dns-APT metrics enabled significant differentiation of LGG versus HGG (AUC: dns-APTmean = 0.78, P < 0.05; dns-APT90 = 0.83, P < 0.05). There was no significant difference regarding MGMT promoter methylation status at any contrast (P > 0.05). Conclusions: Relaxation-compensated multipool CEST MRI, particularly dns-APT imaging, enabled prediction of IDH mutation status and differentiation of LGG versus HGG and should therefore be considered as a non-invasive MR biomarker in the diagnostic workup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.